References
- Shinozaki H., Pharmacology of the glutamat receptor. Prog Neurobiolog 1988; 30: 399–535
- Cotman C. W., Monaghan D. T., Ottersen O. P., Storm-Mathisen J. Anatomical organization of excitatory amino acid receptors and their pathways. Trends Neurosci 1987; 10: 273–80
- Rothman S., Olney J. W. Excitotoxity and the NMDA receptor. Trends Neurosci 1987; 10: 299–302
- Deutsch S., Mastropaolo J., Schwartz B. L., Rosse R. B., Morihtsa J. M. Review. A glutamatergic hypothesis of schizophrenia. Rationale for pharmacotherapy with glycine. Clin Neuropharmacol 1989; 12: 1–13
- Young C. R., Mogenson G. J. Hippocampal signaltransmission to pedunculopotine nucleus and its regulation by dopamine D 2 receptors in nucleus accumbens: An electorphysiological and behavioral study. Neurosci 1987; 23: 1041–55
- Cotman C. W., Iversen L. L. Excitatory amino acid in the brain - focus on NMDA receptors. Trends Neurosci 1987; 10: 263–5
- Honoré T, Davies S. N., Drejer J., Fletcher E. J., Jacobsen P., Lodge D., Nielsen F. E. Quinoxalincdiones: Potent non-NMDA glutamate receptor antagonists. Science 1988; 241: 701–3
- Lublin H., Gerlach J. Behavioral effects of dopamine D-1 and D-2 receptor agonists in monkeys previously treated with haloperidol. Eur J Pharmacol 1988; 153: 239–54
- Lublin H., Gerlach J., Peacock L. Behavioral effects of the selective D-l agonist SKF 81297
- Gerlach J., Casey D. E., Kistrup K., Lublin H. Dopamine D-1 and D-2 receptor functions in acute extrapyramidal syndromes and tardive dyskinesia. Progress in catecholamine research. Part C: Clinical aspects, R.H. Belmaker, M. Sandler, A. Dahlström. Alan Liss, New York, (in press).